Abstract
Abstract: The INK4a/ARF locus on chromosome 9p21 is one of the important defenses against tumor development and engages both the Rb and the p53 tumor suppressor pathways through its capacity to encode two distinct proteins, p16INK4a and p14ARF. Despite controversial reports, the body of present data suggests that tumor suppressors p16INK4a and p14ARF are targets of in‐activation in GEP‐NETs. Moreover, tumor type‐specific aberrant p16INK4a silencing appears to be associated with advanced tumor stage and may function as a predictor of patients' outcome after surgical resection. Since conventional histological and biochemical assessment are limited with respect to predicting GEP‐NET behavior or outcome, methylation profiles including INK4a/ARF might offer a tool to refine future diagnosis and therapeutic management of GEP‐NET patients.